Bristol and Pfizer Get Boost from Apixaban Data

Xconomy New York — 

The experimental drug apixaban (Eliquis), which is being developed by Bristol-Myers Squibb (NYSE: BMY) and Pfizer (NYSE: PFE), met key endpoints in a pivotal Phase 3 trial, according to a press release. The companies plan to apply for approval to market the drug in patients with atrial fibrillation, both in the U.S. and Europe, by the end of the year. Bristol’s stock was up nearly 5 percent in morning trading, reaching $29.30, while Pfizer shares rose 2 percent to $20.78.